pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Reimbursement status of new drugs approved in 2007-2018 (Source: Translated from Korea Institute of Health and Social Affairs, Future Prospect of Pharmaceuticals and Medium to Long-Term Strategy of Health Policy and Governance, 2019)
| Approvedyear | Reimbursement starting year | Sum (%) | Not reimbursed | Total | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||||||
| ’07 | ’08 | ’09 | ’10 | ’11 | ’12 | ’13 | ’14 | ’15 | ’16 | ’17 | ’18 | ’19 | ||||
| ’07 | 13 | 9 | 12 | 2 | 1 | 3 | 1 | 2 | 1 | 1 | 1 | 46 (75.4) | 15 | 61 | ||
| ’08 | 9 | 6 | 7 | 2 | 1 | 25 (58.1) | 18 | 43 | ||||||||
| ’09 | 3 | 9 | 2 | 1 | 4 | 19 (67.9) | 9 | 28 | ||||||||
| ’10 | 10 | 13 | 6 | 1 | 4 | 3 | 37 (77.1) | 11 | 48 | |||||||
| ’11 | 5 | 11 | 9 | 3 | 2 | 1 | 2 | 33 (64.7) | 18 | 51 | ||||||
| ’12 | 6 | 9 | 4 | 4 | 1 | 2 | 26 (68.4) | 12 | 38 | |||||||
| ’13 | 6 | 13 | 4 | 4 | 1 | 28 (71.8) | 11 | 39 | ||||||||
| ’14 | 7 | 25 | 4 | 11 | 2 | 49 (75.4) | 16 | 65 | ||||||||
| ’15 | 18 | 16 | 15 | 6 | 55 (77.5) | 16 | 71 | |||||||||
| ’16 | 2 | 22 | 1 | 25(46.3) | 29 | 54 | ||||||||||
| ’17 | 9 | 10 | 6 | 25 (56.8) | 19 | 44 | ||||||||||
| ’18 | 9 | 6 | 15 (53.6) | 13 | 28 | |||||||||||
| Sum | 13 | 18 | 21 | 28 | 21 | 29 | 27 | 30 | 55 | 33 | 64 | 31 | 13 | 383 (67.2) | 187 | 570 |